WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China company QMing. There was a Series A round worth $11 million. ...
FREDERICK, MD. (PRWEB) JUNE 13, 2018 ...
Inova Health System, through the Office of Research and Commercialization, is excited to share with you the launch of a new research funding initiative, the Inova Translational Research Funding Program (ITRF). This program, which will fund cutting-edge translational research across our system, was created to encourage the development of research talent at Inova and to foster interdepartmental, interinstitutional, academic and industry collaborations. We hope that these partnerships will lead to larger research endeavors that advance our mission to help our patients and our community. ...
Boston, MA (June 5, 2018) – A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator. ...
Baltimore, Maryland (June, 2018)- The Maryland HIMSS Chapter is pleased to announce the opening of their annual call for applications of their Health IT scholarships. Every year, Maryland HIMSS awards two deserving students actively enrolled in a health care information technology and/or computer science related degree program. ...
GAITHERSBURG, MD, June 6, 2018— Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in development of RNAi therapeutics, announces today that it has closed Series C1 financing of US$25 Million (RMB￥160 Million). This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment. The proceeds will be used to expand the clinical programs of the lead anti-fibrosis and anti-cancer RNAi therapeutics, strengthen the management team to support growth ...